DVAHealthcare · Medical Care FacilitiesThe 8 Wall Street analysts covering DaVita, Inc. hold a median 12-month price target of $216 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DaVita, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (55): Analysts have, on balance, been cutting their forecasts.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.1% from it.
Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Barclays | Maintains | Equal-Weight | $224 → $216 |
| 2 Nov 2026 | TD Cowen | Maintains | Buy | $220 → $228 |
| 2 Nov 2026 | UBS | Maintains | Buy | $270 → $287 |
| 7 Aug 2026 | TD Cowen | Upgrade | Buy | $201 → $220 |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $250 → $215 |
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | $218 → $224 |
| 14 July 2026 | Truist Securities | Maintains | Hold | $205 → $250 |
| 14 July 2026 | Truist Securities | Maintains | Hold | — |
| 10 July 2026 | UBS | Maintains | Buy | $235 → $270 |
| 10 July 2026 | UBS | Maintains | Buy | — |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | $194 → $218 |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 11 May 2026 | TD Cowen | Maintains | Hold | — |
| 8 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 8 May 2026 | Truist Securities | Maintains | Hold | — |
| 7 May 2026 | UBS | Maintains | Buy | — |
| 6 May 2026 | Deutsche Bank | Upgrade | Buy | — |
| 4 Feb 2026 | UBS | Maintains | Buy | — |
| 3 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 3 Nov 2025 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DVA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, DaVita, Inc. returned +60.6% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 48% of US stocks
Cheaper than 72% of US stocks
Cheaper than 8% of US stocks
Cheaper than 40% of US stocks
Higher than 39% of US stocks
Higher than 74% of US stocks
Higher than 38% of US stocks
Higher than 73% of US stocks
Higher than 63% of US stocks
Higher than 96% of US stocks
Higher than 87% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DaVita, Inc. has a market value of $11.7B and an enterprise value of $26.2B.
Revenue in the twelve months to 30 June 2026: $14.0B. The latest quarter grew 4.6% year on year.
Net income over the same four quarters: $1.2B, a 8.5% net margin.
Diluted earnings per share, trailing twelve months: $12.22.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
DaVita, Inc. spent $1.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 13.7×; forward P/E: 10.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
DaVita, Inc. employs 78,000 people — $180K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DaVita, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Law Offices of Howard G. Smith said it is investigating whether DaVita may have violated federal securities laws, following an October 20, 2026 disclosure. The firm said investors who suffered losses may have claims to recover them.
Why it matters — The investigation is relevant to DVA watchers because it concerns potential securities-law claims related to DaVita and its investors.
DaVita announced that CFO Joel Ackerman and Group Vice President of Investor Relations Nic Eliason will participate in fireside chats at the UBS Global Healthcare Conference on Nov. 9, 2026, and the Wolfe Research Healthcare Conference on Nov. 10, 2026. Both presentations will be available via live webcast with free registration.
Why it matters — DVA watchers can follow the company’s investor-conference presentations and hear from its finance and investor-relations leaders.
The Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims on behalf of DaVita investors. The inquiry examines whether the company violated federal securities laws in connection with its October 20, 2026 disclosure.
Why it matters — DVA watchers may follow the investigation because it concerns potential legal claims and the company’s disclosures.
DaVita reported Q3 earnings up 52.2% and revenue up 4.6% year over year, beating estimates. Growth was supported by kidney care and international performance, despite rising costs and margin pressure.
Why it matters — The results highlight growth in DaVita’s kidney care and international businesses alongside cost and margin pressures.
DaVita reported third-quarter adjusted operating income of $561 million, adjusted EPS of $3.82 and free cash flow of $276 million, and narrowed its full-year 2026 outlook. Integrated Kidney Care outperformed expectations, while higher technology spending weighed on U.S. dialysis results.
Why it matters — DVA watchers may note the mix of stronger-than-expected Integrated Kidney Care performance and technology-related pressure on U.S. dialysis results alongside the narrowed outlook.
The 8 Wall Street analysts covering DaVita, Inc. have a median 12-month price target of $216, with estimates ranging from $165 to $287. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering DaVita, Inc., 3 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks DaVita, Inc. 88 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, DaVita, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks DaVita, Inc. 88 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DaVita, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $287 over the next 12 months.
DaVita, Inc. returned +60.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease.
The most recent item we track (Business Wire, 4 Nov 2026): "Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G.". The Law Offices of Howard G. Smith said it is investigating whether DaVita may have violated federal securities laws, following an October 20, 2026 disclosure. The firm said investors who suffered losses may have claims to recover them.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease. DaVita provides in-center hemodialysis, peritoneal dialysis, and home dialysis options, along with related clinical support and care coordination services. The company also operates integrated kidney care programs and offers ancillary services that support treatment management and patient care across the kidney health journey. With a large network of dialysis centers in the United States and international markets, DaVita plays a major role in delivering life-sustaining renal care and serving healthcare systems, insurers, and patients who require ongoing treatment.
CEO Mr. Javier J. Rodriguez · 78,000 employees · United States · https://www.davita.com
